Nasdaq
$0.2558▼ 16.27%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $447,851.83Shares out 1.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
26- 9.29Pre-market26.09.29 06:49filed8-KKey event#●●●#●●●
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics approved an increase in authorized common stock from 12.5 million to 100 million shares at its 2026 Annual Meeting held on September 22, 2026. Shareholders also authorized the Board to effect a reverse stock split at a ratio of up to 1:20 and approved an amendment to increase shares issuable under the 2020 Equity Incentive Plan to 400,000.…more
$0.2558-16.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25Pre-market26.09.25 13:15filedEFFECTOther
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. received SEC effectiveness approval for its registration statement (File No. 333-299027) on September 24, 2026. This filing confirms the completion of the legal process required for the company's securities offering.…more
$0.2558-16.27%vs prev closeView filingShare - 9.18After-hours26.09.19 06:30S-1Offering
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics has filed an S-1 registration statement for the resale of up to 4,512,400 shares of common stock issuable upon the conversion of its Series C convertible preferred stock. These shares will be freely tradable, with an estimated offering price of $1.95 per share, totaling approximately $8,799,180 in aggregate value.…more
$0.2558-16.27%vs prev closeView filingShare
25 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 21:07#●●●#●●●
Lakewood-Amedex Presents Nu-3 Antimicrobial Data at IDWeek 2026
Lakewood-Amedex presented research highlighting the antimicrobial efficacy of its lead candidate, Nu-3, against resistant pathogens. The company is currently conducting a Phase 2a clinical trial, with topline data expected in the first quarter of 2027.…more
$0.2558-16.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.7Pre-market26.10.07 21:07
●●●●●●●● ●●●●● ●●●●●●
Lakewood-Amedex announced that its drug candidate Nu-8 demonstrated up to 97% inhibition of E. coli growth in a rodent urinary tract infection model. This result is based on early-stage animal testing and requires further clinical validation.…more
$0.2558-16.27%vs prev closeShareBenzinga - 9.28Pre-market26.09.28 21:09
●●●●●●●● ●●●●● ●●●●●●
Lakewood-Amedex reported that its antimicrobial candidate Nu-3 demonstrated consistent activity against all tested clinical isolates. While the data confirms a favorable therapeutic window, topline results from the ongoing Phase 2a trial are not expected until the first quarter of 2027.…more
$0.2558-16.27%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report